REGN
REGENERON PHARMACEUTICALS, INC.
Nasdaq: REGN · Tarrytown, NY · Healthcare
$805.02-14.07 (-1.72%)Closed
Market Cap$76.00B
Cash$7.99Bmost recent
Runwayprofitable
P/E (TTM)19.4EPS $41.48
52-Wk Range$575.00 – $852.03
Avg Volume857.1K3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$805.02-12.5%
Pipeline

Drug candidates sponsored by REGENERON PHARMACEUTICALS · ClinicalTrials.gov

69 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Praluent
Heterozygous Familial Hypercholesterolemia+1 more
Terminated
2020-04-08past
1
Phase 4dupilumab
Moderate-to-Severe Atopic Dermatitis+6 more
Recruiting
2027-03-30
10
Phase 3rilonacept 160 mg
Familial Cold Autoinflammatory Syndrome (FCAS)+3 more
Completed
2008-06past
1
Phase 3Rilonacept 80 mg
Intercritical Gout
Completed
2010-05past
1
Phase 3ranibizumab
Macular Degeneration
Completed
2010-09past
1
Phase 3Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Branch Retinal Vein Occlusion
Completed
2013-08past
1
Phase 3LMT (atorvastatin, simvastatin, or rosuvastatin)
Heterozygous Familial Hypercholesterolemia
Completed
2014-05past
1
Phase 3Placebo (for alirocumab)
Hypercholesterolemia
Completed
2014-09past
1
Phase 3Suptavumab 30 mg/kg
Respiratory Syncytial Virus Infections
Completed
2017-07-05past
1
Phase 3Fasinumab
Chronic Low Back Pain+4 more
Completed
2020-01-30past
3
Phase 3REGN2810/ipi
Non-small Cell Lung Cancer
Terminated
2021-07-29past
1
Phase 3garetosmab
Fibrodyplasia Ossificans Progressiva (FOP)+1 more
Withdrawn
2022-03-01past
1
Phase 3casirivimab+imdevimab
Immunocompromised
Terminated
2022-05-18past
1
Phase 3evinacumab
Homozygous Familial Hypercholesterolemia+5 more
Completed
2023-04-13past
5
Phase 3REGN2810
Non-small Cell Lung Cancer+1 more
Completed
2025-02-27past
2
Phase 3Aflibercept 8 mg
Neovascular Age-Related Macular Degeneration+1 more
Active, not recruiting
2025-08-26past
1
Phase 3REGN5713
Allergic Conjunctivitis
Terminated
2026-05-02past
1
Phase 3Cemiplimab
Squamous Cell Carcinoma (SCC)+4 more
Active, not recruiting
2026-11-02
6
Phase 3REGN7508
Venous Thromboembolism (VTE)
Recruiting
2027-02-20
1
Phase 3mibavademab
Generalized Lipodystrophy+1 more
Recruiting
2027-06-18
2
Phase 3Linvoseltamab
High Risk Smoldering Multiple Myeloma (HR-SMM)+1 more
Recruiting
2027-08-31
2
Phase 3Odronextamab
Follicular Lymphoma (FL)+6 more
Recruiting
2028-02-07
3
Phase 3REGN-2Cat
Allergic Conjunctivitis
Recruiting
2029-05-31
1
Phase 2VEGF Trap Eye
Macular Degeneration
Completed
2011-10past
1
Phase 2aflibercept
Neovascular (Wet) Age-Related Macular Degeneration
Completed
2021-05-14past
1
Phase 2REGN3918
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Completed
2021-06-09past
1
Phase 2Pozelimab
Paroxysmal Nocturnal Hemoglobinuria+2 more
Completed
2022-05-05past
3
Phase 1cemiplimab (monotherapy)
Relapsed Solid Tumor+5 more
Terminated
2023-05-10past
1
Phase 2CMP-001
Melanoma+4 more
Completed
2024-02-05past
2
Phase 2REGN5381
Uncontrolled Hypertension+1 more
Completed
2025-10-15past
2
Phase 2Trevogrumab-Part A
Obesity
Active, not recruiting
2026-06-16past
1
Phase 2Olatorepatide
Overweight or Obesity+1 more
Active, not recruiting
2026-11-13
2
Phase 1REGN5093
NSCLC
Active, not recruiting
2027-07-06
1
Phase 1REGN5678
Metastatic Castration-Resistant Prostate Cancer (mCRPC)+1 more
Recruiting
2027-11-15
1
Phase 2ALN-HSD
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Recruiting
2028-04-27
1
Phase 2FDC fianlimab+cemiplimab
Head and Neck Squamous Cell Carcinoma (HNSCC)
Recruiting
2028-06-04
1
Phase 2Ubamatamab
Ovarian Cancer+2 more
Recruiting
2028-06-30
1
Phase 1REGN5668
Ovarian Cancer+3 more
Recruiting
2028-11-08
1
Phase 2ALN-CIDEB
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Not yet recruiting
2029-02-06
1
Phase 1REGN4336
Metastatic Castration-resistant Prostate Cancer
Recruiting
2030-03-28
1
Phase 1REGN15505
Metastatic Castration-Resistant Prostate Cancer (mCRPC)+1 more
Recruiting
2030-10-27
1
Phase 1VEGF Trap
Macular Degeneration
Completed
2008-06past
1
Phase 1REGN475 (SAR164877)
Healthy
Completed
2009-11past
1
Phase 1REGN727(SAR236553)
Hypercholesterolemia
Completed
2011-05past
1
Phase 1REGN668: Injection Rate 1
Healthy
Completed
2012-02past
1
Phase 1REGN1154 or placebo
Healthy Volunteers
Completed
2013-01past
1
Phase 1nesvacumab (REGN910/ SAR307746)
Solid Tumors
Completed
2014-11past
2
Phase 1REGN1500
Metabolic Disorders
Completed
2015-09past
1
Phase 1REGN910-3
Neovascular Age-Related Macular Degeneration+1 more
Completed
2015-10past
1
Phase 1REGN1193
Diabetes Mellitus, Type 2
Terminated
2015-12past
1
Phase 1REGN2222
Healthy Volunteers
Completed
2016-09past
1
Phase 1REGN1033
Healthy Volunteers
Completed
2019-04-30past
1
Phase 1REGN5069
Healthy Volunteer
Completed
2019-09-30past
1
Phase 1REGN5713-5714-5715
Healthy Volunteers+1 more
Completed
2020-03-27past
1
Phase 1REGN7999
Healthy
Completed
2023-08-29past
1
Phase 1REGN9035
Healthy Volunteers
Completed
2024-04-02past
1
Phase 1REGN7544
Healthy Volunteers
Completed
2024-07-22past
1
Phase 1Odronextamab multiple dose levels
Non-Hodgkin Lymphoma+1 more
Completed
2025-08-21past
1
Phase 1bbT369
Diffuse Large B Cell Lymphoma (DLBCL)
Terminated
2025-09-19past
1
Phase 1REGN9533
Healthy Volunteer
Completed
2026-01-29past
1
Phase 1REGN20934
Overweight or Obesity
Recruiting
2027-02-22
1
Phase 1REGN9933
End-Stage Kidney Disease (ESKD)
Recruiting
2027-04-02
1
N/AUnnamed
Relapsed/Refractory Follicular Lymphoma
Completed
2023-10-05past
1
N/AUnnamed
Relapsed and Refractory Multiple Myeloma (RRMM)
Completed
2024-09-12past
1
N/ADUPIXENT®
Asthma
Completed
2026-04-27past
1
N/ANoninterventional
Chronic Kidney Disease (CKD)
Recruiting
2027-06-14
1
N/AUnnamed
Conjunctivitis Allergic
Not yet recruiting
2028-01-10
1
N/ANon-interventional
Long Term Safety Following GM T Cell Therapy
Recruiting
2040-06-17
1
N/AREGN5458
Multiple Myeloma
Approved For Marketing—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.